Quantitative coronary computed tomography angiography for the detection of cardiac allograft vasculopathy

Borek Foldyna 1,2,3, Marcus Sandri 4, Christian Luecke 1, Jens Garbade 5, Robin Gohmann 1, Jochen Hahn 5, Julia Fischer 4, Matthias Gutberlet 1, Lukas Lehmkuhl 1,3

Received: 18 June 2019 / Revised: 20 November 2019 / Accepted: 19 December 2019 / Published online: 16 March 2020
© The Author(s) 2020

Abstract

Objectives To associate coronary wall volume and composition, derived from coronary computed tomography angiography (CTA), with cardiac allograft vasculopathy (CAV) detected on invasive coronary angiography (ICA) in heart-transplanted (HTX) patients.

Methods We included consecutive adults who received ICA and coronary CTA for evaluation of CAV ≥ 10 months after HTX. In all coronary segments, we assessed lumen and wall volumes and segmental length, calculated volume-length ratio (VLR) (volumes indexed by segmental length; mm³/mm), wall burden (WB) (wall/wall + lumen volumes; %), and assessed proportions of calcified, fibrotic, fibro-fatty, and low-attenuation tissue (%) in coronary wall. We rendered independent CTA measures associated with CAV by ICA, tested their discriminatory capacity, and assessed concordance between CTA and ICA.

Results Among 50 patients (84% men; 53.6 ± 11.9 years), we analyzed 632 coronary segments. Mean interval between HTX and CTA was 6.7 ± 4.7 years and between ICA and CTA 1 (0–1) day. Segmental VLR, WB, and proportion of fibrotic tissue were independently associated with CAV (OR = 1.06–1.27; p ≤ 0.002), reaching a high discriminatory capacity (combination of all three: AUC = 0.84; 95%CI, 0.75–0.90). Concordance between CTA and ICA was higher in advanced CAV (88%) compared with that in none (37%) and mild (19%) CAV. Discordance was primarily driven by a large number of segments with coronary wall changes on CTA but without luminal stenoses on ICA (177/591; 25%).

Conclusion CTA-derived coronary wall VLR, WB, and the proportion of fibrotic tissue are independent markers of CAV. Combination of these three parameters may aid the detection of early CAV not detected by ICA, the current standard of care.

Key Points
• Coronary CTA detects CAV in HTX patients.
• Coronary wall volume-length ratio, wall burden, and proportion of fibrotic tissue are independently associated with CAV.
• In contrast to ICA, coronary CTA may identify the early stages of CAV.

Keywords Computed tomography angiography · Invasive coronary angiography · Cardiac allograft vasculopathy · Heart transplantation

Matthias Gutberlet and Lukas Lehmkuhl contributed equally to this work.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00330-019-06653-3) contains supplementary material, which is available to authorized users.

Borek Foldyna
bfoldyna@mgh.harvard.edu

1 Department of Interventional and Diagnostic Radiology, University of Leipzig – Heart Center, Struempellstrasse 39, 04289 Leipzig, Germany
2 Cardiovascular Imaging Research Center, Massachusetts General Hospital – Harvard Medical School, Boston, MA, USA
3 Clinic for Radiology, Cardiovascular Center Bad Neustadt, Bad Neustadt, Germany
4 Department of Cardiology, University of Leipzig – Heart Center, Leipzig, Germany
5 University Department for Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany
**Abbreviations**

AUC  | Area under the curve  
CAV  | Coronary allograft vasculopathy  
CHD  | Coronary heart disease  
CTA  | Computed tomography angiography  
HTX  | Heart transplantation  
HU   | Hounsfield units  
ICA  | Invasive coronary angiography  
IQR  | Interquartile range  
IVUS | Intravascular ultrasound  
ROC  | Receiver operating characteristic  
SCCT | Society of Cardiovascular Computed Tomography  
SD   | Standard deviation  
VLR  | Volume-length ratio  
WB   | Wall burden

**Introduction**

Induced by immune and nonimmune triggers, cardiac allograft vasculopathy (CAV) reaches a high incidence of up to 40% in the first 5–8 years after heart transplantation (HTX) and represents the leading cause of graft failure and death among HTX patients [1]. According to recent guidelines, HTX patients should be frequently monitored by invasive coronary angiography (ICA) to detect CAV (class Ia recommendation [2, 3]). However, early CAV is characterized by vascular fibroproliferation and diffuse coronary wall changes without coronary stenosis, unlike advanced CAV, which presents with constrictive remodeling and coronary stenosis [4–7]. While ICA examines merely the coronary lumen, it focuses on stenosis and may miss early stages of CAV which occur as changes of the coronary wall. Supplemental invasive intravascular ultrasound (IVUS) can assess the coronary wall and increase sensitivity [3, 6, 8, 9]. However, IVUS is accompanied by an increased risk of severe complications (up to 4%), including coronary spasm, acute occlusions, embolism, arrhythmia, dissection, and acute thrombosis [8]. Coronary computed tomography angiography (CTA) represents a noninvasive alternative to ICA and IVUS [10–12] and has been successfully used in numerous large trials investigating coronary heart disease (CHD) [13–16] and in smaller studies of CAV [17–19]. Still, it remains unknown whether quantitative CTA measures are associated with CAV and how the diagnosis of CAV using these measures agrees with diagnosis made by ICA.

Thus, the primary aim of this study was to determine CTA-derived quantitative measures of coronary segments (i.e., volumes of the coronary lumen and wall as well as wall composition) in HTX patients and to investigate their association with CAV. Second, we aimed to determine the concordance between CTA and ICA and investigated quantitative CTA measures in all discordant cases.

**Materials and methods**

**Study population**

We included post-HTX adults who underwent routine ICA and coronary CTA for coronary wall imaging at our center for the exclusion (if CAV unknown) or for monitoring of CAV (if CAV known). The time interval between HTX and ICA was at least 10 months and no more than 7 days between ICA and CTA. Patients with acute allograft rejection, contraindications to contrast agents (e.g., severe renal dysfunction; blood creatinine > 1.5 mg/dl), or those who did not undergo ICA and CTA were not included. The local ethics committee approved this retrospective observational cohort study (IRB#442/18ek).

**CTA acquisition and coronary vessel segmentation**

All CTA scans were performed on a second-generation 128-row dual-source CT scanner (Siemens Healthineers) using standard contrast-enhanced, ECG-gated/triggered protocols as described in detail in Supplemental Text S1. An expert reader (B.F.) with > 5 years of experience in coronary CTA analyzed all coronary segments (luminal diameter > 1.5 mm) following the 18-segment model (Society of Cardiovascular Computed Tomography; SCCT) [20] and using dedicated semi-automatic postprocessing software (QAngio, Research Edition, version 2.0.5; Medis Medical Imaging Systems). Left main, proximal right coronary artery, proximal left anterior descending, and proximal circumflex were considered proximal [21]. High reproducibility has been reported for this particular software package (wall burden intra-class correlation coefficient, 0.90 for intra- and 0.84 for inter-observer reliability [12, 19]). (Supplemental Figure S1 shows the individual standard analytic steps as described elsewhere [11, 12, 19, 22].)

**Quantitative coronary CTA analysis**

First, we measured volume (mm$^3$) (lumen and wall) and length (mm) of every coronary segment. Since long segments presented automatically with larger absolute volumes compared with short segments, we indexed all volumes by the length of the given segment. This step standardized the volumes and enabled comparison between segments with different lengths. All indexed volumes were treated as volume-length ratios (VLR; mm$^3$/mm) in all analyses. Analogous to plaque burden calculation in CHD [12, 22], we calculated wall burden (WB), defined as a proportion of coronary wall relative to the size of the entire segment (i.e., wall volume/wall + lumen volume; %).

In a second step, we measured coronary wall composition using dynamic, tissue-specific attenuation thresholds as
previously validated with IVUS [10–12, 23]. Hereby, four tissue types were assessed as absolute volumes (mm$^3$): dense calcium, fibrotic, fibro-fatty, and low-attenuation tissue. To ensure comparability of segments of different sizes, we indexed all absolute values by the segmental wall volume and reported the composition as relative proportions (volume of individual proportion/wall volume; %).

Image quality was evaluated according to the 2014 SCCT guidelines for interpretation and reporting of coronary CTA using a 4-point Likert scale (1 = excellent; 2 = good; 3 = average; 4 = poor) [20]. Segments with poor image quality were excluded from further analysis.

**Invasive coronary angiography**

All angiograms were acquired by experienced cardiologists using standard techniques according to the most recent guidelines and standard protocol in our clinic (Supplemental Text S2). An expert reader (M.S.) with > 6 years of ICA experience interpreted all angiograms, was blinded to all CTA findings, and used the SCCT 18-segment model [20] to ensure comparability with CTA. All coronary lesions were classified visually according to stenosis grade and type as recommended by the American College of Cardiology/American Heart Association (ACC/AHA) Task Force guidelines (grade 0, 0–24%; 1, 25–49%; 2, 50–74%; 3, 75–90% and > 90%; 4, 100% and type A, < 10 mm length, concentric; B, 10–20 mm length, eccentric; and C, > 20 mm length, excessive tortuosity) [24]. We classified CAV-positive segments as follows: no CAV, no stenosis or stenosis 1–24%; mild CAV, stenosis grade 25–49%, type A or B; ≥ moderate CAV, stenosis ≥ 50% and type A–C.

**Statistical analysis**

Continuous variables were expressed as mean ± standard deviation (SD) or median (interquartile range; IQR), while categorical variables were listed as frequencies and percentages. To increase readability, we tabulated all values as mean ± SD and restricted the use of the median (IQR) to highly skewed or ordinal-scaled data. Differences of CTA measures between CAV-positive vs. CAV-negative patients were tested with the Wilcoxon rank-sum or Fisher’s exact test, as appropriate. Associations of individual CTA measures with CAV by ICA were tested with univariate logistic regression. Subsequently, we rendered independent CTA variables using multivariate regression, including all variables which were associated with CAV in the univariate analyses ($p < 0.05$). In a supplemental analysis, we provided univariate and multivariate results adjusted for segment location (proximal vs. distal).

After building a multivariate logistic regression model, which included all CTA variables independently associated with CAV, we calculated relative probability of having CAV in each coronary segment (continuous measure with range, 0–1; equation provided in Supplemental Text S3). Using these probabilities, we computed areas under receiver operator curve (AUC/ROC) as measures of discriminatory capacity to detect CAV. Differences between AUC curves were tested with the likelihood-ratio test for nested models. In an explorative analysis, we estimated a threshold for the CTA-derived probability using the Youden index [25] (equal weight on sensitivity and specificity) including sensitivity and specificity for the given threshold.

Finally, we categorized the CTA-based probability into tertiles (i.e., low, intermediate, and high) and tabulated these against the CAV grades on ICA (none, mild, and ≥ moderate). We assessed the concordance between CTA and ICA and identified groups of segments with the highest concordance and discordance. Level of significance was defined as two-sided $p < 0.05$, and Stata 15.0 was used for all statistical analyses.

**Results**

**Study population and evaluable coronary segments**

Among 42 (84%) men and 8 (16%) women (mean age of 53.6 ± 11.9 years), who were included in the analytic cohort, CAV prevalence was 38% (19/50) on ICA. The mean interval between HTX and CTA was 6.7 ± 4.7 years, while the median interval between ICA and CTA was 1 (0–1) day. Dilative cardiomyopathy (58.0%) was the most frequent indication for HTX, and the most common comorbidities were renal dysfunction (44%), dyslipidemia (26%), and diabetes mellitus (22%). Detailed demographics and medical treatment information are provided in Table 1 and Supplemental Table S1, respectively.

| Table 1 | Patient characteristics |
|---------|-------------------------|
| Demographics | All (n = 50) |
| Age, years | 53.4 ± 12.0 |
| Male, n (%) | 42 (84) |
| BMI, kg/m² | 27.0 ± 3.9 |
| Primary indication for HTX, n (%) | | |
| Dilatative cardiomyopathy | 29 (58) |
| Ischemic heart disease | 16 (32) |
| Other | 5 (10) |
| Cardiovascular risk factors, n (%) | | |
| Diabetes | 11 (22) |
| Art. hypertension | 6 (12) |
| Hyperlipidemia | 13 (26) |
| Atrial fibrillation | 4 (8) |
| Peripheral artery disease | 2 (4) |
| Renal disorder | 22 (44) |
| Current smoker | 2 (4) |

$BMI$ body mass index
Despite relatively high heart rate (mean 74.1 ± 8.5 bpm), the median image quality was rated as good (IQR, excellent–good); (correlation of heart rate with image quality, \( r = 0.28; p = 0.05 \)). Ultimately, 56 segments had poor image quality and were excluded from the analysis. Median dose length product and effective dose were 413.5 (225.0–678.0) mGy cm and 5.8 (3.2–9.5) mSv, respectively.

Overall, 692 coronary segments were evaluable on CTA, and among these, 632/692 (91.4%) segments had a corresponding partner on ICA. Hence, the final analytic sample consisted of 632 coronary segments, of which 190/632 (30.1%) and 442/632 (69.9%) segments were classified as proximal and distal, respectively.

### Quantitative coronary CTA analysis

On CTA, the mean wall and lumen VLRs were 7.7 ± 3.2 and 5.8 ± 4.7 mm\(^3\)/mm, respectively, while the mean WB was 59.1 ± 8.6% (Table 2). WB was higher in distal coronary segments (62% vs. 56%; \( p < 0.001 \)), while coronary lumen and wall VLRs were twofold lower compared with the proximal segments (lumen, 4.4 ± 3.1 vs. 9.5 ± 6.0 mm\(^3\)/mm, and wall, 6.7 ± 2.5 vs. 10.0 ± 3.3 mm\(^3\)/mm; \( p < 0.001 \) for both; Supplemental Table S2).

Regarding composition, coronary walls consisted of 44.7% fibrotic, 18.6% fibro-fatty, 8.5% low-attenuation, and 1.0% calcified tissue (Table 2), while the remaining 27.2% were outside of the tissue-specific thresholds (e.g., media border). Here is to be noted that the proportion of fibrotic tissue was significantly higher, while proportions of calcified, fibro-fatty, and low-attenuation tissue were significantly lower in the distal compared with that in proximal coronary segments (\( p < 0.001 \) for all; Supplemental Table S2).

### Invasive coronary angiography

On ICA, 19/50 (38%) patients and 41/632 (6.5%) coronary segments were rated as CAV-positive. Among patients with at least one coronary lesion, median 1 (1–3) segments were classified as CAV-positive on ICA. Single-, double-, and triple-vessel diseases were present in 12/19 (63%), 4/19 (21%), and 3/19 (16%) patients, respectively. Median stenosis grade was 2 (2–2) (50–75% luminal stenosis), while the most frequent lesion type was B (25/49; 51%) followed by C (18/49; 37%) and A (6/49; 12%).

### Quantitative coronary CTA measures in segments with and without CAV on ICA

Coronary wall VLR was significantly larger in the 41 CAV-positive segments compared with those without CAV (10.6 ± 4.5 vs. 7.5 ± 2.9 mm\(^3\)/mm; \( p < 0.001 \)). On the other hand, coronary lumen VLR did not differ significantly between CAV-positive and CAV-negative segments (\( p = 0.864 \)). Accordingly, WB was higher in segments with CAV compared with those without CAV (66.3 ± 10.0 vs. 59.5 ± 8.4%; \( p < 0.001 \)).

Regarding the wall composition, CAV-positive coronary segments had more fibrotic tissue (48.7 ± 11.4 vs. 44.4 ± 11.1%; \( p = 0.033 \)) and dense calcium (4.2 ± 6.1 vs. 0.8 ± 2.3%; \( p < 0.001 \)) compared with CAV-negative segments. Proportions of fibro-fatty and low-attenuation tissue did not differ between CAV-positive and CAV-negative segments (\( p = 0.204 \) and 0.163, respectively) (Table 2).

In the univariate logistic regression, coronary wall VLR, WB, and calcified and fibrotic tissue were associated with CAV (OR = 1.04–1.28; \( p \leq 0.019 \) (ORs per mm\(^3\)/mm or % increase as appropriate) (Table 3). In the multivariate analysis, coronary wall VLR, WB, and fibrotic tissue remained independently associated with CAV (OR = 1.27; \( p < 0.001 \), OR = Table 2

| CTA measures                     | All segments (n = 632) | CAV-negative on ICA (n = 591) | CAV-positive on ICA (n = 41) | \( p \) |
|---------------------------------|------------------------|-------------------------------|-----------------------------|-----|
| Volume-length ratio, mm\(^3\)/mm|                        |                               |                             |     |
| Lumen                           | 5.8 ± 4.0              | 5.8 ± 4.7                     | 5.9 ± 5.0                   | 0.864 |
| Wall                            | 7.7 ± 3.2              | 7.5 ± 2.9                     | 10.6 ± 4.5                  | <0.001 |
| Wall burden, %                  | 59.1 ± 8.6             | 59.5 ± 8.4                    | 66.3 ± 10.0                 | <0.001 |
| Composition, %                  |                        |                               |                             |     |
| Dense calcium                   | 1.0 ± 2.8              | 0.8 ± 2.3                     | 4.2 ± 6.1                   | <0.001 |
| Fibrotic tissue                 | 44.7 ± 11.2            | 44.4 ± 11.1                   | 48.7 ± 11.4                 | 0.033 |
| Fibro-fatty tissue              | 18.6 ± 7.8             | 18.7 ± 7.8                    | 17.4 ± 7.4                  | 0.204 |
| Low-attenuation tissue          | 8.5 ± 6.6              | 8.6 ± 6.7                     | 7.1 ± 6.1                   | 0.163 |

CAV cardiac allograft vasculopathy; CTA computed tomography angiography; ICA invasive coronary angiography
1.09; \( p < 0.001 \), and OR = 1.06; \( p = 0.002 \), respectively) (Table 3). All three CTA measures remained significantly associated with CAV after further adjustment for segment location (\( p \leq 0.002 \) for all; Supplemental Table S3).

Mean CTA-derived probability to have CAV was 6 ± 11% (range 0–97%) (derived from logistic model nesting coronary wall VLR, WB, and fibrotic tissue; Supplemental Text S3 provides the corresponding formula for calculation of individual combined probability). The probability reached a high discriminatory capacity for CAV (AUC = 0.83; 95% CI, 0.75–0.90) (Fig. 1). Even though the quantitative CTA did not focus on accessing luminal stenosis and, therefore, was not directly comparable with ICA, in a direct exploratory comparison of CTA vs. ICA, the sensitivity and specificity were relatively high (78% and 75%, respectively, by using a threshold of 5% calculated by the Youden index).

**Concordance CTA vs. ICA**

Overall, there was a moderate concordance of 37% (233/632) between the coronary CTA and ICA (Table 4). As expected, the concordance was substantially higher in those with advanced disease (22/25 (88%)) compared with those with none or mild disease on ICA (208/591 (37%) and 3/16 (19%), respectively). Focusing on the extremes, namely the difference of two categories, coronary CTA classified 177/632 (28%) segments as a high probability for having CAV without a corresponding correlate on ICA. Not surprisingly, the discordant 177 segments had higher coronary wall VLR, WB, and more fibrotic tissue (\( p < 0.001 \) for all) compared with segments with low and intermediate probability and no CAV on ICA. Figure 2c provides an example of a discordant case. Moreover, the discordant segments were more frequently distal segments (112/177 (63%) vs. 65/177 (37%); \( p = 0.012 \)). On the other hand, only 1/632 (0.2%) segment was classified as a low probability by CTA but presented with ≥moderate CAV on ICA.

**Discussion**

In this study, we investigated the association of quantitative coronary CTA with CAV and explored the concordance between CTA and ICA. This study had two major findings: (1) CTA-derived coronary wall volume-length ratio, wall burden, and proportion of fibrotic tissue were independently associated with CAV; and (2) concordance between CTA and ICA was high in advanced CAV, while discordance was driven predominantly by distal coronary segments with changes of coronary wall on CTA but without CAV on ICA. Our study identified the CTA-derived coronary wall VLR, WB, and proportion of fibrotic tissue as independent measures of CAV; corroborated the high performance of CTA to detect advanced CAV; and revealed a potential advantage of quantitative CTA in early stages of CAV.

Due to rapid technical progress, coronary CTA has become an alternative to ICA for the exclusion of CHD in patients with chest pain [13–15, 26, 27] and has received Ib recommendation in the most recent 2019 European Society of Cardiology guidelines for the diagnosis and management of chronic coronary syndromes [28]. However, coronary CTA has not become a routine procedure to detect CAV in HTX patients yet (class IIb recommendation [3]). In HTX patients, the primary concern is image quality. The limiting factor, influencing the image quality, is the frequently observed high heart rate and a limited response of HTX patients to heart rate modulation (e.g., beta-blockers).

While in older scanners image quality depended strongly on the heart rate [29–31], recent studies have shown that contemporary CTA technology reaches diagnostic image quality
in HTX patients with heart rates > 70 bpm at reasonable radiation exposure (4.3–6.6 mSv) [18, 19, 32, 33]. Our study endorses these results by revealing good image quality at a mean heart rate of 74 bpm and median effective radiation dose of 5.8 mSv. One could argue that the effective dose in CTA is higher than the reported average median effective dose of diagnostic ICA (3.3 mSv) [34]. Nevertheless, several recent studies using the most recent CTA technology have reported excellent images at effective dose of 0.3–2.9 mSv despite heart rates above 70 bpm or heart rhythm irregularities [35–37]. Therefore, further advances in temporal resolution and introduction of novel protocols, combining low kVp and iterative reconstruction algorithms, will likely lead to a further decline of radiation necessary for diagnostic image quality in HTX patients.

Considering the technical improvement of coronary CTA, it is not surprising that qualitative detection of obstructive coronary stenoses (≥50%) on CTA agrees well with ICA not only in patients with CHD but also in HTX patients (negative predictive value, 98–100%) [17, 27, 33, 38, 39]. Quantitative coronary wall analysis has become a supplementary tool to qualitative CTA by providing additional information about coronary wall volume and composition. In patients with CHD, quantitative CTA has revealed a good agreement with IVUS [11, 12] and has become a standard to monitor changes of atherosclerotic plaques in numerous studies using serial CTA [40–43]. Nevertheless, there is only limited evidence about the utilization of quantitative CTA in HTX patients. For instance, Karolyi et al used serial CTA to show that quantitative assessment of coronary walls is feasible to measure coronary wall changes over time and that progression of coronary wall volume is driven by noncalcified components [19]. Our study underlines the feasibility and enhances these results by identifying coronary wall VLR, WB, and proportion of fibrotic tissue as independent indicators of CAV.

Regarding pathophysiology of CAV, our results confirmed a series of histopathological studies which have shown that CAV is primarily driven by fibroproliferation [4–7], reflected in a higher proportion of fibrotic tissue in CAV-positive segments. Moreover, CAV has been reported to progress typically in a biphasic manner. Namely, CAV progression starts with an initial phase, including early intimal thickening with an expansion of the external elastic membrane and relative preservation of the lumen. The initial phase is then followed by an

---

Table 4 CTA vs. ICA for the detection of CAV

| CAV probability by CTA* | None | Mild | ≥Moderate | Total |
|-------------------------|------|------|-----------|-------|
| T1: low (< 2%)          | 208 (32.9) | 2 (0.3) | 1 (0.2) | 211 (33.3) |
| T2: medium (2.0–4.5%)   | 206 (32.6) | 3 (0.5) | 2 (0.3) | 211 (33.3) |
| T3: high (> 4.5%)       | 177 (28.0) | 11 (1.7) | 22 (3.5) | 211 (33.3) |
| Total                   | 591 (93.5) | 16 (2.5) | 25 (4.0) | 632 (100.0) |

The discordance between CTA and ICA was driven by segments which have shown large coronary wall changes on CTA but were not classified as CAV-positive by the ICA (n = 177; red lower left field). *Based on the logistic regression including coronary wall volume-length ratio, wall burden, and proportion of fibrotic tissue. CAV = cardiac allograft vasculopathy; CTA = computed tomography angiography; ICA = invasive coronary angiography.
advanced phase with constrictive remodeling and luminal stenosis [5, 7]. While ICA captures merely the coronary lumen, it may miss the early phases of CAV. The fact that CTA enables measurements of coronary walls regardless of luminal stenosis may explain why our sensitivity and specificity of quantitative CTA (78% and 75%, respectively) were lower than the usually reported values for qualitative CTA (assessment of significant stenosis (≥ 50%); 94% and 92%, respectively) [33].

The reason becomes even more apparent if investigating the concordance between quantitative CTA and ICA. We found a high concordance (88%) between both methods in advanced CAV, which confirms that lesions with coronary wall changes and lumen narrowing are detectable by both methods accurately. These results are in accord with a meta-analysis by Wever-Pinzon et al, who investigated the accuracy of qualitative CTA to detect CAV in comparison with ICA [33]. However, the discordance was driven by segments which were classified as CAV-positive by CTA and CAV-negative by ICA (i.e., segments with coronary wall changes but without a luminal stenosis; example, Fig. 2c). In fact, quantitative CTA has shown significant coronary wall changes in 28% of segments rated as normal on ICA (Tab. 4). Vice versa, CTA rated only one (0.2%) coronary segment as a low probability of having CAV while the ICA reported advanced CAV. These findings are striking and suggest a higher sensitivity and a higher negative predictive value of quantitative CTA for the detection of early CAV compared with ICA. Future prospective studies with less mechanistic and more prognostic endpoints (e.g., survival) are needed to confirm this hypothesis.

Moreover, the discordance between CTA and ICA was the highest in distal coronary segments, those not always accessible by IVUS, underlining the importance to evaluate the entire coronary tree, representing a clear advantage of CTA compared with IVUS. Indexing of segmental volumes by segmental length (i.e., VLR) and treating coronary wall components as proportions standardized the values and permitted comparison of segments at different locations. In a supplemental analysis, we showed that segmental VLR, WB, and proportion of fibrotic tissue are all independently associated with CAV even after adjustment for segment location. The independence of segment location further emphasizes the robustness and generalizability of the quantitative CTA measures.

In general, coronary walls and lumen were smaller, while WB and proportion of fibrotic tissue were higher in the distal coronary segments compared with those in the proximal segments. In other words, in the course of the vessel, the lumen became smaller while the wall did not get necessarily thinner. This observation should get further attention in future studies to investigate whether an increasing WB towards distal coronary segments reflects normal anatomy or also a sign of CAV.

Potential clinical implications of our results may include earlier detection of CAV leading to a sooner initiation or more aggressive regimen of medical therapy, intensification of...
follow-up visits, and more intensive management of risk factors. Notably, in our cohort, > 80% of patients were on NSAR and statins, and around 60% received tacrolimus/everolimus, which seem to be the most effective treatment/prevention strategy for CAV. While the long-term efficacy of these last-named medications remains unclear [44], quantitative CTA may represent a novel tool to monitor not only the progression of CAV but also the effects of immunosuppressive drugs. In fact, quantitative coronary CTA has been successfully utilized for monitoring of coronary plaques in patients receiving statins [40, 45, 46] in contrast to earlier studies, such as the SATURN trial [47], which traditionally relayed on IVUS.

We acknowledge several limitations of this retrospective single-center observational cohort study. First, we included only HTX patients and did not compare the CTA results with general population. Thus, future studies, preferably in individuals without known CHD, should define normal values of VLR, WB, and fibrotic tissue. We did not have information about the cardiovascular risk profile of our heart donors, and preexisting CHD may have influenced our measurements (e.g., calcifications). Serial approaches, which would include a baseline CTA exam and would focus on changes of the qualitative CTA measures during follow-up, may provide more insights into the pathogenesis of CAV. Moreover, the sample size in our study was relatively small. Future larger studies should include the evaluation of clinical outcomes and investigate the incremental value of quantitative over qualitative CTA.

Conclusion

Coronary CTA-derived wall VLR, WB, and proportion of fibrotic tissue were independently associated with CAV on ICA. While the concordance between CTA and ICA was high in advanced CAV, the discordance was mainly driven by distal coronary segments showing changes of coronary walls on CTA but without corresponding stenosis on ICA. These segments may represent those with non-stenotic coronary wall changes, related to early stages of CAV. Thus, quantitative CTA, in particular the combination of VLR, WB, and proportion of fibrotic tissue, may aid the detection of early CAV, guide medical treatment, and ultimately improve patients' outcomes.

Funding information Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is Lukas Lehmkuhl, MD.

Conflict of interest The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry One of the authors has significant statistical expertise. No complex statistical methods were necessary for this paper.

Informed consent Written informed consent was waived by the Institutional Review Board.

Ethical approval Institutional Review Board approval was obtained.

Methodology

- Retrospective
- Observational
- Performed at one institution

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lund LH, Edwards LB, Kucheryavaya AY et al (2015) The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplantation report—2015; focus theme: early graft failure. J Heart Lung Transplant 34:1244–1254. https://doi.org/10.1016/j.healun.2015.08.003

2. Badano LP, Miglioranza MH, Edvardsen T et al (2015) European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation. Eur Heart J Cardiovasc Imaging 16:919–948. https://doi.org/10.1093/ehjci/jev139

3. Costanzo MR, Dipchand A, Starling R et al (2010) The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 29:914–956. https://doi.org/10.1016/j.healun.2010.05.034

4. Chih S, Chong AY, Mielenzuk LM, Bhatt DL, Beanlands RS (2016) Allograft vasculopathy: the Achilles’ heel of heart transplantation. J Am Coll Cardiol 68:80–91. https://doi.org/10.1016/j.jacc.2016.04.033

5. Hiemann NE, Wellhofer E, Knosalla C et al (2007) Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation 116:1274–1282. https://doi.org/10.1161/CIRCULATIONAHA.106.647149

6. Torres HJ, Merello L, Ramos SA et al (2011) Prevalence of cardiac allograft vasculopathy assessed with coronary angiography versus coronary vascular ultrasound and virtual histology. Transplant Proc 43:2318–2321. https://doi.org/10.1016/j.transproceed.2011.06.002

7. Tsutsui H, Zaida KM, Schoenhagen P et al (2001) Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling. Circulation 104:653–657. https://doi.org/10.1161/hc3101.093867
38. Günther A, Aaberge L, Abildgaard A et al (2018) Coronary computed tomography in heart transplant patients: detection of significant stenosis and cardiac allograft vasculopathy, image quality, and radiation dose. Acta Radiol 59:1066–1073. https://doi.org/10.1007/0284185117748354

39. Miller JM, Rochitte CE, Dewey M et al (2008) Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 359:2324–2336. https://doi.org/10.1056/NEJMoa0806576

40. Lo J, Lu MT, Ihenachor EJ et al (2015) Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2:e52–e63. https://doi.org/10.1016/S2352-3018(14)00032-0

41. Foldyna B, Fourman LT, Lu MT et al (2018) Sex differences in subclinical coronary atherosclerotic plaque among individuals with HIV on antiretroviral therapy. J Acquir Immune Defic Syndr 78:421–428 https://doi.org/10.1097/QAI.0000000000001686

42. Shin S, Park H-B, Chang H-J et al (2017) Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT angiography study. JACC Cardiovasc Imaging 10:437–446. https://doi.org/10.1016/j.jcmg.2016.04.013

43. Li Z, Hou Z, Yin W et al (2016) Effects of statin therapy on progression of mild noncalcified coronary plaque assessed by serial coronary computed tomography angiography: a multicenter prospective study. Am Heart J 180:29–38. https://doi.org/10.1016/j.ahj.2016.06.023

44. Langstraat M, Musters KJS, Manintveld O, Masetti M, Potena L (2018) Coronary artery disease in heart transplantation: new concepts for an old disease. Transpl Int 31:787–827. https://doi.org/10.1111/tri.13141

45. Foldyna B, Lo J, Mayrhofer T, Grinspoon SK, Hoffmann U, Lu MT (2019) Individual coronary plaque changes on serial CT angiography: within-patient heterogeneity, natural history, and statin effects in HIV. J Cardiovasc Comput Tomogr. https://doi.org/10.1016/j.jcct.2019.08.011

46. Lee S-E, Chang H-J, Sung JM et al (2018) Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. JACC Cardiovasc Imaging 11:1475–1484. https://doi.org/10.1016/j.jcmg.2018.04.015

47. Puri R, Nicholls SJ, Shao M et al (2015) Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 65:1273–1282. https://doi.org/10.1016/j.jacc.2015.01.036

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.